Vaxeal Holding SA - Product Pipeline Review - 2014

Published: Sep, 2014 | Pages: 21 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Vaxeal Holding SA - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Vaxeal Holding SA - Product Pipeline Review - 2014', provides an overview of the Vaxeal Holding SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Vaxeal Holding SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Vaxeal Holding SA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Vaxeal Holding SA's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Vaxeal Holding SA's pipeline products

Reasons to buy

- Evaluate Vaxeal Holding SA's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Vaxeal Holding SA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Vaxeal Holding SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Vaxeal Holding SA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vaxeal Holding SA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Vaxeal Holding SA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Vaxeal Holding SA Snapshot 4
Vaxeal Holding SA Overview 4
Key Information 4
Key Facts 4
Vaxeal Holding SA - Research and Development Overview 5
Key Therapeutic Areas 5
Vaxeal Holding SA - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Vaxeal Holding SA - Pipeline Products Glance 9
Vaxeal Holding SA - Early Stage Pipeline Products 9
Preclinical Products/Combination Treatment Modalities 9
Discovery Products/Combination Treatment Modalities 10
Vaxeal Holding SA - Drug Profiles 11
MDX-1 Vaccine 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
SVX-1 Vaccine 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
Vaccine For Hepatitis C 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Cancer Combination Vaccine 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
CBX-1 Vaccine 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Vaxeal Holding SA - Pipeline Analysis 16
Vaxeal Holding SA - Pipeline Products by Target 16
Vaxeal Holding SA - Pipeline Products by Molecule Type 17
Vaxeal Holding SA - Dormant Projects 18
Vaxeal Holding SA - Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Appendix 20
Methodology 20
Coverage 20
Secondary Research 20
Primary Research 20
Expert Panel Validation 20
Contact Us 21
Disclaimer 21

List of Tables
Vaxeal Holding SA, Key Information 4
Vaxeal Holding SA, Key Facts 4
Vaxeal Holding SA - Pipeline by Indication, 2014 6
Vaxeal Holding SA - Pipeline by Stage of Development, 2014 7
Vaxeal Holding SA - Monotherapy Products in Pipeline, 2014 8
Vaxeal Holding SA - Preclinical, 2014 9
Vaxeal Holding SA - Discovery, 2014 10
Vaxeal Holding SA - Pipeline by Target, 2014 16
Vaxeal Holding SA - Pipeline by Molecule Type, 2014 17
Vaxeal Holding SA - Dormant Developmental Projects,2014 18
Vaxeal Holding SA, Subsidiaries 19